Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes

被引:33
作者
Peyrade, Frederic [1 ]
Cupissol, Didier [2 ]
Geoffrois, Lionel [3 ]
Rolland, Frederic [4 ]
Borel, Christian [5 ]
Ciais, Catherine [6 ]
Faivre, Sandrine [7 ]
Guigay, Joel [8 ]
机构
[1] Ctr Antoine Lacassagne, Dept Med Oncol, F-06186 Nice 2, France
[2] Ctr Val dAurelle, Dept Med Oncol, Montpellier, France
[3] Ctr Alexis Vautrin, Dept Med Oncol, Vandoeuvre Les Nancy, France
[4] Inst Cancerol Ouest, Dept Med Oncol, St Herblain, France
[5] Ctr Paul Strauss, Dept Med Oncol, Strasbourg, France
[6] Ctr Antoine Lacassagne, Dept Support Care, F-06186 Nice 2, France
[7] Hop Beaujon, Dept Med Oncol, Paris, France
[8] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
关键词
Cetuximab; Chemotherapy; Metastatic squamous cell carcinoma of the head and neck; Recommendations; Supportive care; Targeted therapy; COMPREHENSIVE GERIATRIC ASSESSMENT; CONTROLLED-RELEASE OXYCODONE; CISPLATIN PLUS FLUOROURACIL; MULTICENTER PHASE-II; RANDOMIZED-TRIAL; NEUROPATHIC PAIN; DIABETIC-NEUROPATHY; EORTC GUIDELINES; ELDERLY-PATIENTS; OPEN-LABEL;
D O I
10.1016/j.oraloncology.2013.01.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Worldwide, head and neck carcinomas account for 5% of all malignancies. Two-thirds of patients relapse after initial multimodal therapy. Until early 2000, the median overall survival (OS) of metastatic patients was about 6 months. Recently, new drugs have been incorporated in patient management, thus enabling an increase in OS. This review aims to define the comprehensive medical management of patients with relapsing head and neck carcinoma. Methods: A comprehensive review of the literature was made targeting four topics: first-and second-line treatment, supportive care, and management of elderly patients. Results: The choice of first-or second-line treatments is mainly based on performance status. In the elderly, geriatric assessment could be helpful. For PS 0.1 patients, the standard first-line treatment is 6 cycles of cisplatin-5FU-cetuximab. In the event of response, cetuximab alone is prolonged until progression or unacceptable toxicity. For second-line treatment, several options are currently available: enrolment in clinical trials, single-agent therapy (methotrexate, taxane, cetuximab), and best supportive care (BSC). Supportive care has to be initiated very early in the course of the disease to prevent pain, dysphagia and malnutrition. In elderly patients, the therapeutic options are: first-line treatment with the EXTREME regimen replacing cisplatin by carboplatin for patients in good general condition or methotrexate alone for other patients. BSC continues to be given to all patients (i.e. poor general conditions). Conclusion: In spite of numerous pending issues requiring further investigation, these recommendations seem to be routinely applicable. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:482 / 491
页数:10
相关论文
共 75 条
  • [1] 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    Aapro, M. S.
    Bohlius, J.
    Cameron, D. A.
    Dal Lago, Lissandra
    Donnelly, J. Peter
    Kearney, N.
    Lyman, G. H.
    Pettengell, R.
    Tjan-Heijnen, V. C.
    Walewski, J.
    Weber, Damien C.
    Zielinski, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (01) : 8 - 32
  • [2] [Anonymous], J CLIN ONCOL
  • [3] [Anonymous], J CLIN ONCOL S
  • [4] Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck - An analysis of two Eastern Cooperative Oncology Group randomized trials
    Argiris, A
    Li, Y
    Forastiere, A
    [J]. CANCER, 2004, 101 (10) : 2222 - 2229
  • [5] Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy
    Argiris, A
    Li, Y
    Murphy, BA
    Langer, CJ
    Forastiere, AA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) : 262 - 268
  • [6] Argiris A., 2011, J CLIN ONCOL S, V29
  • [7] Prophylactic Percutaneous Endoscopic Gastrostomy in Patients With Advanced Head and Neck Tumors Treated by Combined Chemoradiotherapy
    Assenat, Eric
    Thezenas, Simon
    Flori, Nicolas
    Pere-Charlier, Nicole
    Garrel, Renaud
    Serre, Antoine
    Azria, David
    Senesse, Pierre
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2011, 42 (04) : 548 - 556
  • [8] The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy
    Atasoy, Beste M.
    Yonal, Oya
    Demirel, Birsen
    Dane, Faysal
    Yilmaz, Yusuf
    Kalayci, Cem
    Abacioglu, Ufuk
    Imeryuz, Nese
    [J]. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2012, 269 (01) : 275 - 282
  • [9] Balducci L, 2000, Oncologist, V5, P224, DOI 10.1634/theoncologist.5-3-224
  • [10] Gabapentin for the Treatment of Pain Syndrome Related to Radiation-Induced Mucositis in Patients With Head and Neck Cancer Treated With Concurrent Chemoradiotherapy
    Bar, Voichita
    Weinstein, Gregory
    Dutta, Pinaki R.
    Dosoretz, Arie
    Chalian, Ara
    Both, Stefan
    Quon, Harry
    [J]. CANCER, 2010, 116 (17) : 4206 - 4213